惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

V
Visual Studio Blog
Recent Announcements
Recent Announcements
雷峰网
雷峰网
The GitHub Blog
The GitHub Blog
罗磊的独立博客
月光博客
月光博客
J
Java Code Geeks
A
About on SuperTechFans
Microsoft Security Blog
Microsoft Security Blog
D
Docker
OSCHINA 社区最新新闻
OSCHINA 社区最新新闻
F
Fortinet All Blogs
U
Unit 42
C
Check Point Blog
Martin Fowler
Martin Fowler
有赞技术团队
有赞技术团队
博客园 - 叶小钗
Cyber Security Advisories - MS-ISAC
Cyber Security Advisories - MS-ISAC
酷 壳 – CoolShell
酷 壳 – CoolShell
Blog — PlanetScale
Blog — PlanetScale
大猫的无限游戏
大猫的无限游戏
让小产品的独立变现更简单 - ezindie.com
让小产品的独立变现更简单 - ezindie.com
阮一峰的网络日志
阮一峰的网络日志
MyScale Blog
MyScale Blog

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Lon...
SA Transcripts · 2026-06-23 · via All Articles on Seeking Alpha

Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation June 22, 2026 8:00 AM EDT

Company Participants

Paul Little - Chief Financial Officer
David-Alexandre Gros - CEO & Non Independent Director
Steven Perrin - President, Chief Scientific Officer & Non Independent Director

Conference Call Participants

Thomas Smith - Leerink Partners LLC, Research Division
Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division
Vamil Divan - Guggenheim Securities, LLC, Research Division
Rami Katkhuda - LifeSci Capital, LLC, Research Division
Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division

Presentation

Operator

Good morning, ladies and gentlemen, and welcome to The American Transplant Congress Data Update Call. [Operator Instructions]. This call is being recorded on Monday, June 22, 2026. I would now like to turn the conference over to Paul Little, Chief Financial Officer. Please go ahead.

Paul Little
Chief Financial Officer

Good morning, everyone, and thank you for joining our BESTOW Long-term data update conference call. I'm joined on today's call by David-Alexandre Gros, Chief Executive Officer, Steve Perrin, our President and Chief Scientific Officer; and David Hovland, our Chief Regulatory Officer.

Earlier today, Eledon issued a press release detailing the updated clinical results presented at the American Transplant Congress. You may access the release and this presentation under the Investors tab on our company's website at eledon.com.

I would like to remind everyone that statements made during the conference call relating to Eledon's expected future performance, future business plans, our future events or plans may include forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual outcomes and results could differ materially from these forecasts due to the impact of many factors beyond the control of Eledon. Eledon expressly